Food And Drug Administration Center For Biologics Evaluation And Research

Vaccines And Related Biological Products Advisory Committee Meeting September 22 and 23, 2004

Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD 20814

Draft AGENDA

Day 1

8:15 AM Closed Session

9:45 AM Break/Adjourn Closed Session

Open Session

Presentation of Tetravalent Meningococcal Conjugate Vaccine

Sponsor: Aventis Pasteur Inc.

Product: Menactra

10:00 AM	Call to Order	Dr. Gary Overturf, Chair
10:05 AM	Announcements	Christine Walsh R.N., FDA
10:15 AM	Introduction to the License Application	Dr. Carl Frasch, FDA
	What is the product	
	Requested indication	
	Regulatory history	
10:30 AM	Clinical Data in Support of Menactra	Aventis Pasteur Representative
11:15 AM	Questions of Clarification for Applicant	
11:30 AM	Break	
11:45 AM	Clinical Review of Safety and Efficacy	Dr. Lucia Lee, FDA
12:30 PM	Questions of Clarification for FDA	
12:45 PM	Lunch	
12:45 PM 2:00 PM	Lunch Open Public Hearing	
2:00 PM	Open Public Hearing	
2:00 PM 2:30 PM	Open Public Hearing Presentation of Questions for Committee	Dr. Carl Frasch, FDA
2:00 PM 2:30 PM 2:45 PM	Open Public Hearing Presentation of Questions for Committee Committee Discussion/Voting on Questions	Dr. Carl Frasch, FDA
2:00 PM 2:30 PM	Open Public Hearing Presentation of Questions for Committee	Dr. Carl Frasch, FDA
2:00 PM 2:30 PM 2:45 PM	Open Public Hearing Presentation of Questions for Committee Committee Discussion/Voting on Questions	
2:00 PM 2:30 PM 2:45 PM 3:30 PM	Open Public Hearing Presentation of Questions for Committee Committee Discussion/Voting on Questions Break	

Food And Drug Administration Center For Biologics Evaluation And Research Vaccines And Related Biological Products Advisory Committee Meeting September 22 and 23, 2004

Holiday Inn, 8120 Wisconsin Ave., Bethesda, MD 20814

Draft AGENDA

Day 2

Open Session

Thailand HIV Vaccine Phase 3 Trial

Trial Sponsor: Office of the Surgeon General of the Army

Products: HIV-1 Recombinant Canarypox-Vectored Vaccine (ALVAC vCP1521) [Aventis Pasteur], and Recombinant gp120 B/E (CHO cells) with Alum [VaxGen]

9:00 AM	Call to Order	Dr. Gary Overturf, Chair
9:05 AM	Announcements	Christine Walsh R.N., FDA
9:15 AM	Opening Remarks	Dr. Joseph Toerner, FDA
9:25 AM	Presentation by the Sponsor	LTC Brown, DoD
	Overview of Study RV144,	
	Rationale for Proceeding with Phase III St	udy
10:00 AM	Questions of Clarification from Committee	
10:15 AM	Open Public Hearing	
10:45 AM	Break/Adjourn Open Session	

11:00 AM Closed Session

12:15 PM Adjourn